WHAT IS BLINCYTO® (blinatumomab)?
BLINCYTO® is a prescription medicine used to treat adults and children with:

B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease)...read more

BLINCYTO® is a prescription medicine used to treat adults and children with:

B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body ...read more

B-cell precursor ALL that has come back or did not respond to previous treatments

ALL is a cancer of the blood in which a particular kind of white blood cell is growing out of control.
This site is intended for US residents only.
Important Safety Information Prescribing Information Medication Guide Indication Health Care Professionals Contact Us

How you'll receive BLINCYTO®

BLINCYTO® is given by a continuous intravenous (IV) infusion. This means the medicine goes into your body through a vein. This happens for a 4-week period.1,2

The dosing of BLINCYTO® occurs in cycles. Here’s how a cycle works:1

BLINCYTO® (blinatumomab) dosing

One cycle is 4 weeks of continuous infusion followed by 2 weeks without infusion.1

In the study of BLINCYTO® for MRD, most people were given 1 or 2 cycles.3 Your doctor will decide how long you will need to stay on treatment.

What to expect when you start BLINCYTO® (blinatumomab)

What to expect when you start BLINCYTO®

BLINCYTO® treatment starts in the hospital to make sure that it is safe for you and to prevent and manage any side effects that may occur.1

  • You’ll be given a medicine to help reduce the likelihood of infusion reactions, which are common for medicines like BLINCYTO®4
  • You will be monitored and treated for any serious reactions to BLINCYTO® if they happen4
BLINCYTO® (blinatumomab) treatment
For the first cycle, a hospital stay of 3 days is recommended.1
BLINCYTO® (blinatumomab) treatment
For the second cycle, a hospital stay of 2 days is recommended.1

Afterward, your doctor will decide if you can get the rest of your treatment at home, if that is right for you. Or your doctor may refer you to an outpatient clinic or an infusion center to manage your treatment.

BLINCYTO® (blinatumomab) IV bag
After your hospital stay, you will continue BLINCYTO® with a small, portable IV infusion pump. BLINCYTO® is available in 24-hour, 48-hour, and 7-day infusion bags. Your bag will either need to be changed every day, every 2 days, or once a week based on what your doctor decides is best for you.1

Receiving BLINCYTO® at home

If it feels overwhelming to receive BLINCYTO® away from the hospital, you have support options. Your health care team may be able to help make sure you are prepared. Here are some notes about receiving BLINCYTO® at home:

BLINCYTO® (blinatumomab) IV bag
Talk to your health care provider about whether your IV bag will be changed at an outpatient center or by your home health care provider.
BLINCYTO® (blinatumomab) call your doctor
Call your doctor if you experience any problems or side effects.
BLINCYTO® (blinatumomab) pump recommendations
Do not change the settings on your pump, even if the alarm sounds. Any setting changes may cause a dose error.
BLINCYTO® (blinatumomab) outpatient treatment
If you are having any problems with your pump, or pump alarm sounds, contact your health care provider immediately.
BLINCYTO® (blinatumomab) treatment recommendations
Keep BLINCYTO® and all medicines out of reach of other children in the household.
BLINCYTO® (blinatumomab) downloadable resource

Download The Treatment Tracker

This calendar helps you keep track of scheduled appointments and bag changes.

Important Safety Information

What is the most important information I should know about BLINCYTO®?

  • Call your health care provider or get emergency medical help right away if you get any of the symptoms listed below:
    • BLINCYTO® may cause serious side effects that can be severe, life-threatening, or lead to death, including:
      • Cytokine Release Syndrome (CRS) and infusion reactions. Symptoms of CRS and infusion reactions may include: fever, tiredness or weakness, dizziness, headache, low blood pressure, nausea, vomiting, chills, face swelling, wheezing or trouble breathing, and skin rash.
      • Neurologic problems. Symptoms of neurologic problems may include: seizures, difficulty in speaking or slurred speech, loss of consciousness, trouble sleeping, confusion and disorientation, loss of balance, headache, difficulty with facial movements, hearing, vision, or swallowing, and tremors.
    • Your health care provider will check for these problems during treatment with BLINCYTO®. Your health care provider may temporarily
      or completely stop your treatment with BLINCYTO® if you have severe side effects.

Who should not receive BLINCYTO®?

  • Do not receive BLINCYTO® if you are allergic to blinatumomab or to any of the ingredients of BLINCYTO®.

Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:

    • have a history of neurological problems, such as seizures, confusion, trouble speaking or loss of balance
    • have an infection
    • have ever had an infusion reaction after receiving BLINCYTO® or other medications
    • have a history of radiation treatment to the brain, or chemotherapy treatment
    • are scheduled to receive a vaccine. You should not receive a “live vaccine” within 2 weeks before you start treatment with BLINCYTO®, during treatment, and until your immune system recovers after you receive your last cycle of BLINCYTO®. If you are not sure about the type of vaccine, ask your health care provider.
    • are pregnant or plan to become pregnant. BLINCYTO® may harm your unborn baby. Tell your health care provider if you become pregnant during treatment with BLINCYTO®.
      • If you are able to become pregnant, your health care provider should do a pregnancy test before you start treatment with BLINCYTO®.
      • Females who are able to become pregnant should use an effective form of birth control during treatment with BLINCYTO®,
        and for 48 hours after your last dose of BLINCYTO®.
    • are breastfeeding or plan to breastfeed. It is not known if BLINCYTO® passes into your breast milk. You should not breastfeed during treatment with BLINCYTO® and for 48 hours after your last dose.
    Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What should I avoid while receiving BLINCYTO®?

  • Do not drive, operate heavy machinery, or do other dangerous activities while you are receiving BLINCYTO® because BLINCYTO® can cause neurological symptoms such as dizziness, seizures, and confusion.

BLINCYTO® may cause serious side effects, including:

  • Infections. BLINCYTO® may cause life-threatening infections that may lead to death. Tell your health care provider right away in
    case you develop any signs or symptoms of an infection.
  • Tumor Lysis Syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can be life-threatening and may
    lead to death. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with BLINCYTO,
    including: nausea and vomiting, confusion, shortness of breath, irregular heartbeat, dark or cloudy urine, reduced
    amount of urine, unusual tiredness, muscle cramps.
  • Low white blood cell counts (neutropenia). Neutropenia is common with BLINCYTO® treatment and may sometimes be life-threatening. Low white blood cell counts can increase your risk of infection. Your health care provider will do blood tests to check
    your white blood cell counts during treatment with BLINCYTO®. Tell your health care provider right away if you get a fever.
  • Abnormal liver blood test. Your health care provider will do blood tests to check your liver before you start BLINCYTO® and during
    treatment with BLINCYTO®.
  • Inflammation of the pancreas (pancreatitis). Pancreatitis may happen in patients treated with BLINCYTO® and corticosteroids. It may
    be severe and lead to death. Tell your health care provider right away if you have severe stomach-area pain that does not go away. The
    pain may happen with or without nausea and vomiting.
  • Your health care provider will do blood tests during treatment to check for side effects.

The most common side effects

  • The most common side effects of BLINCYTO® include:
    • Fever
    • Reactions related to infusion of the medicine such as face swelling, low blood pressure, and high blood pressure (infusion-related reactions)
    • Infections
    • Headache
    • Low red blood cell count (anemia)
    • Low white blood cell count (neutropenia)
    • Low platelet count (thrombocytopenia)

These are not all the possible side effects of BLINCYTO®.

Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please read the accompanying Medication Guide before you or your child receives BLINCYTO® and before each BLINCYTO® infusion and discuss it with your doctor.

Please see BLINCYTO® full Prescribing Information, including BOXED WARNINGS and Medication Guide.

Important Safety Information

What is the most important information I should know about BLINCYTO®?

  • Call your health care provider or get emergency medical help right away if you get any of the symptoms listed below:
    • BLINCYTO® may cause serious side effects that can be severe, life-threatening, or lead to death, including:
      • Cytokine Release Syndrome (CRS) and infusion reactions. Symptoms of CRS and infusion reactions may include: fever, tiredness or weakness, dizziness, headache, low blood pressure, nausea, vomiting, chills, face swelling, wheezing or trouble breathing, and skin rash.
      • Neurologic problems. Symptoms of neurologic problems may include: seizures, difficulty in speaking or slurred speech, loss of consciousness, trouble sleeping, confusion and disorientation, loss of balance, headache, difficulty with facial movements, hearing, vision, or swallowing, and tremors.
  • Your health care provider will check for these problems during treatment with BLINCYTO®. Your health care provider may temporarily or completely stop your treatment with BLINCYTO® if you have severe side effects.

References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. National Cancer Institute. NCI dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed October 8, 2019. 3. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522-1531. 4. BLINCYTO® (blinatumomab) medication guide, Amgen.